Abstract: Radiofrequency ablation (RFA)is an advanced, minimally invasive technique in the treatment of patients with lung cancer and has been found to be both safe and technically feasible with a high local efficacy, but for he size of the lesion is over 3.0 cm diameter there is less effective. Iodine-131-labeled nuclei of tumor cells chimeric monoclonal antibody, a novel radioimmunotherapy provided a new therapeutic approaches for lung cancer, but the complete response is low. For RFA can induce a mass complete tumor necrosis which greatly increase the targeting area for radioimmunotherapy, thus RFA followed by ¹³¹I-nuclei of tumor cells chimeric monoclonal antibody adjuvant treatment may apparently improve the therapeutic efficacy of lung cancer, especially for tumors larger than 3.0 cm diameter.